Tuberculosis cost-effectiveness of therapy

Tuberculosis treatment must be evaluated for relative cost-effectiveness of inpatient and outpatient models of care as it will benefit regions where tuberculosis is endemic. It is highly recommended to treat the TB patient in ambulatory care instead of inpatient setting unless there are severe complications.^[1]

While measurements of morbidity and mortality are important considerations for estimating the burden of disease in populations, they give an incomplete picture of the adverse effect of sickness on human welfare especially the economic consequences of poor health that may be substantial.

Analysis of the economic effect of the disease addresses multiple policy questions regarding the results of disease. Some of these questions are associated with the microeconomic level of households, firms, or government – such as the effect of the disease on a household’s income or a firm’s profits – while others relate to the macroeconomic level, including the cumulative effect of a disease on a country’s currency and future gross domestic product (GDP).

WHO suggests a outlined conceptual framework within which the economic burden of diseases and injuries can be appropriately estimated. ^[2]

The cost of the current regimen is approximately 4000 US$ per patient excluding laboratory, human resource, and patient opportunity costs. ^[3]

The cost-effectiveness in various tubercular control interventions in Africa region is given below. ^[3]

Template:WH Template:WS